Treatment of Delirium Tremens in a Patient with Respiratory Distress

1. Immediate Assessment and Triage

• Acute confusion, agitation, vivid hallucinations (visual/tactile)
• Autonomic hyperactivity: fever, tachycardia, hypertension, diaphoresis
• Marked tremor

• Transfer to ICU immediately (Maudsley Prescribing Guidelines, 15th ed., p. 506)
• Continuous cardiac and pulse oximetry monitoring
• Assess the cause of respiratory distress (aspiration pneumonia, ARDS from sepsis, hypoventilation from CNS depression, pulmonary edema from cardiomyopathy, or rib fractures from falls/trauma)
• CT head to rule out subdural hematoma (common in this population due to falls)
• Chest X-ray, ABG, BMP, LFTs, Mg, phosphate, CBC

2. The Core Tension: Sedation vs. Respiratory Drive

3. First-Line Treatment: Benzodiazepines

4. Adjuncts to Reduce Benzodiazepine Requirement (Important in Respiratory Distress)

• Dexmedetomidine - an alpha-2 agonist more potent than clonidine; onset 15 min, half-life 2 hours. Key advantage: decreases sympathetic tone WITHOUT causing respiratory depression (Kaplan & Sadock Comprehensive Textbook, p. 9819). Particularly suitable in a patient with respiratory distress who is NOT yet intubated, or as a benzodiazepine-sparing agent in the ICU.
• Clonidine 0.1-0.2 mg PO/IV q6h - reduces autonomic hyperactivity but not suitable as sole therapy.

• Atenolol 25-50 mg PO or propranolol 10-40 mg q6-8h to control tachycardia and hypertension (Goldman-Cecil, Table 364-5). Adjunctive only - do not prevent seizures.

5. Refractory DT: When Benzodiazepines Are Insufficient

• 65 mg IV every 15-30 min to a maximum of 260 mg (Tintinalli's EM, Table 185-2)
• Critical warning in respiratory distress: Phenobarbital causes respiratory depression MORE commonly than benzodiazepines and typically requires intubation before or immediately after use (Tintinalli's EM)
• Recent studies (PMID 42260228, 39262224) compare phenobarbital vs. benzodiazepines in the ICU setting; generally equivalent outcomes, but phenobarbital's respiratory risk must be factored in

• 5 mcg/kg/min (0.3 mg/kg/hr) IV, titrated to effect
• Requires intubation - not appropriate in a non-intubated patient with respiratory distress
• Used when patient is already on mechanical ventilation (Tintinalli's EM, Goodman & Gilman)

• Can be used as primary adjunct or add-on for benzodiazepine-refractory DT
• Critical advantage: no respiratory depression, making it ideal in respiratory compromise
• Requires ICU monitoring for bradycardia and hypotension

6. If the Patient Needs Intubation

• SpO2 < 90% despite supplemental O2
• Rising PaCO2 / respiratory acidosis
• Inability to protect airway (aspiration risk is high in agitated DT patients)
• Need for phenobarbital or propofol to control refractory DT
• Exhaustion / respiratory fatigue

7. Essential Supportive Measures (Do Not Omit)

8. Monitor and Avoid

• Phenothiazines (chlorpromazine, etc.): Avoid - reduce seizure threshold (Adams & Victor)
• Phenytoin: Does NOT prevent alcohol withdrawal seizures when used alone or with benzodiazepines (Maudsley, 15th ed.)
• Rapid correction of hyponatremia: Risk of osmotic demyelination syndrome
• CIWA-Ar scoring is useful to titrate benzodiazepine doses but requires patient cooperation; in severe agitation, fixed + PRN dosing may be more practical in the ICU

Summary Algorithm for DT + Respiratory Distress

DT + Respiratory Distress
        │
        ├─ Mild-moderate distress, SpO2 maintained
        │        → IV lorazepam/diazepam titrated
        │        → Add dexmedetomidine (respiratory-safe adjunct)
        │        → Thiamine, Mg, K, fluids
        │        → Low threshold to intubate
        │
        └─ Severe distress / refractory agitation / SpO2 declining
                 → INTUBATE EARLY
                 → Post-intubation: propofol infusion ± midazolam ± dexmedetomidine
                 → Phenobarbital if refractory (now safe after intubation)
                 → Continue all supportive measures

• Tintinalli's Emergency Medicine, Table 185-2
• Adams and Victor's Principles of Neurology, 12th ed., pp. 1197-1198
• Maudsley Prescribing Guidelines in Psychiatry, 15th ed., pp. 505-506
• Goldman-Cecil Medicine, Table 364-5
• Kaplan & Sadock's Comprehensive Textbook of Psychiatry, p. 9819
• Goodman & Gilman's Pharmacological Basis of Therapeutics
• Recent ICU comparative studies: Phenobarbital vs. BZD in ICU (2025) (PMID 39262224), Phenobarbital vs. dexmedetomidine (2025) (PMID 40152196)

Neurological Complications of Cocaine and Ketamine Withdrawal

Important clarification on framing: The user's question asks about "cocaine or ketamine withdrawal." It's important to distinguish between:

• Cocaine: Has a well-defined withdrawal syndrome with significant neurological/neuropsychiatric features
• Ketamine: Withdrawal is less well-characterized pharmacologically; its neurological complications arise mainly from chronic use/abuse (neurotoxicity), though cessation-related phenomena do exist Both are covered in full below.

PART 1: Cocaine Withdrawal - Neurological and Neuropsychiatric Complications

Mechanism of Cocaine's CNS Action

• Rosen's Emergency Medicine, p. 2472; Goodman & Gilman, p. 1044

The Three Phases of Cocaine Withdrawal

• Severe depression and dysphoria
• Intense cocaine craving
• Agitation and anxiety
• Exhaustion and hypersomnia (rebound REM sleep with vivid nightmares)
• Hyperphagia
• Tremulousness
• Profuse sweating, headache, muscle cramps, stomach cramps
• Bradycardia (autonomic rebound)

• Normalized sleep and mood initially, but episodic:
• Anxiety, restlessness, anhedonia
• Intense drug craving (the major danger for relapse)
• Mild cognitive blunting and reduced concentration

• Gradual resolution but persistent vulnerability to relapse
• Episodic craving triggered by cues (conditioned stimuli)

Neurological and Neuropsychiatric Complications Specific to Withdrawal

1. Severe Depression

• "The most serious withdrawal symptom is depression, which can be particularly severe after sustained use of high doses of stimulants and can be associated with suicidal ideation or behavior." - Kaplan & Sadock Synopsis, p. 964
• Residual depression after cocaine withdrawal should be treated with antidepressants if it persists. - Goodman & Gilman, p. 565

2. Stimulant-Induced Psychotic Disorder (during use, persisting into withdrawal)

• Paranoid delusions and hallucinations in up to 50% of those who misuse stimulants
• Auditory hallucinations common; visual and tactile less so
• Formication (sensation of bugs crawling under skin - "cocaine bugs") - tactile hallucination
• More common with IV use and crack cocaine
• Can persist beyond acute intoxication, overlapping with early withdrawal
• Treatment: short-term antipsychotics (haloperidol)
• Kaplan & Sadock Synopsis, p. 964-965

3. Stimulant Intoxication Delirium / Withdrawal Confusion

• Confusion and cognitive disorganization, especially after binge use combined with sleep deprivation
• The cocaine abstinence syndrome includes: depression, irritability, lethargy, lack of motivation, hypersomnolence, confusion, and drug craving
• Kaplan & Sadock Comprehensive, p. 4324

4. "Cocaine Washout" Syndrome

• After a cocaine binge, users enter a profoundly sedated, obtunded state
• Arousable and oriented when stimulated; normal or mildly bradycardic vital signs
• Results from catecholamine depletion, disrupted salt/water balance, and malnutrition
• Rosen's EM, p. 2650

5. Stimulant-Induced Anxiety Disorder

• Panic attacks and phobic symptoms can onset during withdrawal as well as intoxication
• Reflects rebound serotonergic/noradrenergic dysregulation
• Kaplan & Sadock Synopsis, p. 965

6. Stimulant-Induced Mood Disorder

• During intoxication: manic/mixed features
• During withdrawal: depressive features dominate
• May represent a genuine induced bipolar-spectrum disorder
• Kaplan & Sadock Synopsis, p. 965

7. Neurological Complications from Chronic Use (Relevant at Withdrawal Presentation)

• Cerebrovascular accident (stroke): Cocaine causes intense cerebral vasoconstriction; both ischemic and hemorrhagic stroke are described. May present or worsen during the washout/withdrawal period when vasoconstriction dynamics change.
• Seizures: Cocaine lowers seizure threshold via sodium channel blockade and dopaminergic excitation. Withdrawal from chronic use is not classically associated with seizures (unlike alcohol), but seizures can occur in the setting of binge use/crash.
• Cognitive impairment: Chronic cocaine use is associated with deficits in attention, executive function, memory, and processing speed that may partially persist into withdrawal.
• Psychiatric comorbidities: Anxiety disorders, depression, and psychosis may pre-exist, be worsened, or be unmasked by cocaine withdrawal.
• Goodman & Gilman, p. 1044; Rosen's EM, p. 2640

Treatment of Cocaine Withdrawal - Neurological Aspects

"There are no medications approved by the FDA to treat cocaine addiction." - Goodman & Gilman, p. 565

PART 2: Ketamine - Neurological Complications

Important Framing: Ketamine vs. True "Withdrawal"

Mechanism of Ketamine Neurotoxicity

• Compensatory upregulation of NMDA receptors and excitatory glutamatergic pathways
• Altered GABAergic inhibition (post-cessation studies show sustained GABA-A receptor modulation)
• Disruption of hippocampal and prefrontal cortical circuits
• Goldman-Cecil Medicine; Miller's Anesthesia

Neurological Complications of Chronic Ketamine Use / Withdrawal State

1. Cognitive Impairment

• Impaired memory (episodic and working memory)
• Deficits in attention, executive function, processing speed
• Dissociative symptoms (depersonalization, derealization) that persist beyond the acute drug effect
• A meta-analysis (PMID 35568275) confirmed significant acute cognitive effects of ketamine/esketamine in healthy subjects; chronic use amplifies these
• These deficits may partially persist during and after withdrawal

2. Neuropsychiatric Complications at Cessation

• Dysphoria and depression - reflecting NMDA-receptor rebound hypersensitivity and loss of glutamatergic modulation
• Anxiety and panic
• Flashbacks and dissociative episodes - ketamine persisting or rebound dissociation
• Insomnia
• Drug craving - dopaminergic reward pathway dysfunction

3. Ketamine-Induced Psychosis

• Chronic high-dose use produces a schizophrenia-like syndrome: positive symptoms (hallucinations, delusions) and negative symptoms (flat affect, social withdrawal, cognitive blunting)
• This is the basis for ketamine's use as a pharmacological model of schizophrenia in research
• May persist or worsen at drug cessation before resolving

4. Direct Neurological Effects (at High Doses / Chronic Use)

• Increased cerebral blood flow and potential seizure activity (Goldman-Cecil)
• White matter changes on neuroimaging have been described in chronic ketamine abusers (especially in East/Southeast Asian populations where recreational ketamine abuse is prevalent)
• Neurotoxicity with apoptosis in cortical and hippocampal neurons has been documented in animal models; GPX4/NLRP3 pyroptosis pathways implicated in neonatal cognitive impairment (PMID 40404947)
• Uroschizis (Ketamine Bladder Syndrome) - while primarily urological, associated with upper tract disease and can have secondary neurological effects from uremic complications in severe cases

5. Ketamine Cravings and Psychological Dependence

• Unlike opioids or alcohol, physical withdrawal from ketamine is mild - primarily psychological
• Craving is mediated through the dopaminergic reward (mesolimbic) pathway - the same circuitry affected by cocaine
• Craving is intense and a major obstacle to cessation

Summary Comparison Table

• Goodman & Gilman's Pharmacological Basis of Therapeutics, Table 28-9, pp. 1044-1049
• Kaplan & Sadock's Synopsis of Psychiatry, pp. 963-965 (Stimulant Withdrawal, Stimulant-Induced Psychotic Disorder)
• Kaplan & Sadock's Comprehensive Textbook of Psychiatry, p. 4324
• Rosen's Emergency Medicine, pp. 2640-2656 (Cocaine Use Disorder, Washout)
• Forensic Medicine & Toxicology, 36th ed., pp. 9316-9328 (Cocaine Withdrawal Phases)
• Goldman-Cecil Medicine (Ketamine pharmacology)
• Meta-analysis: Ketamine & cognitive effects (PMID 35568275)
• Ketamine neonatal neurotoxicity (PMID 40404947)